MUC16
- Known as:
- MUC16
- Catalog number:
- Y214496
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- MUC16
Related genes to: MUC16
- Gene:
- MUC16 NIH gene
- Name:
- mucin 16, cell surface associated
- Previous symbol:
- -
- Synonyms:
- CA125, FLJ14303
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-07-20
- Date modifiied:
- 2015-09-04
Related products to: MUC16
Related articles to: MUC16
- The early diagnosis of ovarian cancer remains dissolved due to the lack of detection methods that are sensitive, rapid and accessible. To address this clinical challenge, this study developed an innovative diagnostic platform integrating a novel selenium nanoparticles (SeNPs) probe, dual-biomarker (CA125 and HE4) detection and intelligent analysis system. The detection limits for CA125 and HE4 were determined to be 35 U/mL and 100 pmol/L respectively, and no cross-reactivity was observed. Capitalizing on computer vision and AI prompt engineering technology, this study implemented smartphone-based image acquisition combined with AI-assisted analysis. The results of 360 clinical samples testing indicated that the coincidence rate of this kit with chemiluminescence method was over 95%, and the AUC of the combined detection of dual markers reached 0.914. By integrating the ROMA algorithm, the risk probability of ovarian cancer can be calculated in real time based on the test results and the patient's menopausal status, enabling quantitative risk assessment. This study provides a stable, highly specific, cost-effective and clinically decision supported point-of-care diagnostic solution for the early screening of ovarian cancer, promoting the development of POCT technology towards intelligence and precision. - Source: PubMed
Publication date: 2026/03/23
Xie WeiqiWu JinboXie XiaoyiWu MengliZhang MenghanZhang MengyaoLi XiaoquanWang LiWang LanjuLiu ZhigangWang ZhizengChen Chunxia - Alpha-fetoprotein-producing gastric cancer (AFPGC) represents a distinct clinical entity within the landscape of gastric malignancies, characterized by its aggressive biological behavior and unique clinicopathological profile. Most cases are classified under the chromosomal instability (CIN) subtype, featuring a molecular signature often marked by and mutations, as well as significant amplifications of genes like ERBB2 and the cell cycle regulator CCNE1. As a serum tumor marker, alpha-fetoprotein (AFP) is typically highly elevated in AFPGC and correlates closely with tumor T-stage and patient prognosis. However, discordant expression is observed in some cases, characterized by positive intra-tumoral AFP expression in the presence of normal serum AFP levels. Moreover, intra-tumoral AFP plays an important role in both tumor invasiveness and immune evasion. It may promote tumor pro-liferation and metastasis by modulating immune cell activity. The high malignant potential of AFPGC may be attributable to its capacity to actively remodel the tumor milieu toward an immunosuppressive phenotype. Clinical studies have shown that the co-elevation of AFP with other markers, such as carcinoembryonic antigen (CEA), human chorionic gonadotropin (HCG), and protein induced by vitamin K absence or antagonist-Ⅱ (PIVKA-Ⅱ) often indicates a high malignant potential and a poor prognosis in gastric cancer, particularly in patients with advanced disease. Such concurrent detection of two or more biomar-kers facilitates the assessment of tumor aggressiveness as well as provides a clinical basis for early diagnosis and prognostic evaluation. Currently, there are no standardized guidelines for AFPGC treatment, and strategies often rely on individual pathological profile, tumor staging, and biomarker levels. In addition, immune checkpoint inhibitors (ICIs) have shown preliminary efficacy in some cases. Immunotherapy has demonstrated potential in AFPGC treatment, but the overall therapeutic outcomes and underlying mechanisms of resistance warrant further clinical validation and investigation. Individualized and multimodal therapeutic approaches are fundamental to improving clinical outcomes due to the high degree of heterogeneity in AFPGC. Therefore, a comprehensive evaluation of serum AFP levels, radiological findings, and pathological characteristics is essential for the development of personalized treatment regimens. - Source: PubMed
Luo BixianLiu HongmingXie WeixunGong Weihua - The contribution of activated Hepatic Stellate Cells (aHSCs) to cholestatic fibrosis and cancer is well documented, but the role of portal fibroblasts (PFs), and especially Msln-Muc16-Thy-1 signaling in aPFs, is unknown. - Source: PubMed
Publication date: 2026/04/10
Sakane SadatsuguNishio TakahiroFuji HiroakiPark Se YongIshizuka KeiMiciano CharleneKimura YusukeHosseini MojganDiggle KarinZhang VivianLee WonseokKim Hyun YoungLiu XiaoWang AllenBrenner David AKisseleva Tatiana - T-cell engagers (TCEs) are a diverse class of bispecific and multispecific molecules that co-bind CD3 on T cells and tumor-associated antigens to form an immune synapse and induce targeted T-cell-mediated cytotoxicity. While TCEs have demonstrated remarkable efficacy in hematologic malignancies, translation into solid tumors has been more challenging. Recent advances seen with tebentafusp in metastatic uveal melanoma and tarlatamab in small-cell lung cancer have validated the approach and driven a rapidly expanding pipeline targeting other tumor associated antigens such as STEAP1, MUC16, and PRAME among others. Unique challenges in solid tumors include antigen heterogeneity and density thresholds, on-target/off-tumor toxicities, and physical and immunologic barriers within the tumor microenvironment. To address these, next-generation engineering strategies, such as half-life extension, protease- or context-dependent masking, multispecificity, and "armed" constructs incorporating cytokine or co-stimulatory payloads, are being developed to enhance intratumoral activity while limiting systemic toxicities. Combination regimens with checkpoint blockade, chemotherapy, targeted therapies, and oncolytic platforms are also being actively investigated to overcome immune resistance and improve durability of response. Collectively, next-generation TCEs guided by rational target selection, context-dependent activation, and biomarker-driven patient stratification, are poised to broaden the reach of immunotherapy in solid tumors. In this review, we synthesize the recent advances that aim to expand the therapeutic window of TCEs for the treatment of solid tumors. - Source: PubMed
Publication date: 2026/04/08
Garcia-Lorenzo EstherDorta MiriamDoger BernardPedregal ManuelMoreno Victor - Sensitive and specific blood biomarkers for early detection of colorectal (CRC), lung (LuCa) and ovarian (OvCa) cancers are highly warranted. The current blood tests often need to be complemented with other clinical methods to achieve adequate diagnostic performance. Recent progress in the molecular profiling of plasma from cancer patients holds potential for improved non-invasive screening. Here, we aimed to identify composite proteomic and metabolomic plasma biomarkers for early cancer detection with performances that exceed those of existing FDA-approved blood and stool-based diagnostic tests for CRC, LuCa and OvCa. - Source: PubMed
Publication date: 2026/04/07
Ögren Jim ÅkerrénEkström JoakimRameika NatalliaTorell EmmaLarsson ChatarinaStoimenov IvayloMicke PatrickGyllensten UlfHellström MatsGlimelius BengtStålberg KarinSjöblom Tobias